Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Abstract

BACKGROUNDUnderstanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. METHODSWe conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. RESULTSWe report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki's disease-like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). CONCLUSIONSMultisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.

Post nCoV-2 limping Child: Report of two cases and a rapid Review

“…They might be experienced hospitalization with the risk of superinfection and bacterial colonization (12). Case reports have appeared describing the pediatric patients with unusual presentations of Kawasaki s disease, toxic shock syndrome, acute abdominal conditions, and encephalopathy, macrophage activation syndrome, along with other reports of patients with fever, elevated in ammatory markers, and multisystem involvement as a new entity called childhood multisystem in ammatory syndrome (13).…”

A global assessment of the impact of school closure in reducing COVID-19 spread

“…This highlights the critical importance of conducting periodic social contact surveys in different parts of the world for informing epidemic surveillance and control of a wide range of infectious diseases including COVID-19, influenza, TB, RSV, measles, etc. Finally, we must remain alert to the evolving understanding about the multisystem inflammatory syndrome in children associated with COVID-19 27 , especially as it relates to whether ethnic or other special subgroups amongst this age cohort could be particularly susceptible to this phenotype 28 .…”

Establishment of a Pediatric COVID-19 Biorepository: Unique Considerations and Opportunities for Studying the Impact of the COVID-19 Pandemic on Children

“…Following a mild or symptomatic infection of COVID-19, children can develop a severe, post-infectious in ammatory response syndrome, termed Multisystem In ammatory Syndrome in Children (MIS-C), which is characterized by hyperin ammatory shock [18], "Kawasaki-like" cardiac damage, and possible death [19]. Risk factors for developing MIS-C and biomarkers predicting severe complications need to be identi ed.…”